Suicidal behavior (SB) is a major public health problem in France, with more than 10,000 suicides and 220,000 suicide attempts per year. According to the commonly accepted model for understanding suicidal behavior, individuals who carry a suicidal act when subjected to stress factors (environmental stress, depression, substance ...) are those which have a specific vulnerability. These vulnerabilities can be considered as clinical parameters (propensity to despair, aggressive and/or impulsive traits), neurobiological parameters (dysfunction of the serotonergic system, ...) and cognitive parameters (taking disadvantageous decision ...). Suicidal vulnerability is partly underpinned by genetic factors. The interest of current researches is to identify biomarkers that will improve the opportunities for early identification of subject with a risk for SB. Numerous scientific studies, including post-mortem studies of the brains of suicide completers, have established a link between dysregulation of the ribonucleic acids editing (RNA) of certain genes, the enzymatic activity of Adenosine deaminases acting on RNA (ADARS) responsible for this edition and suicidal behavior. A prospective study is needed to quantify and qualify in the blood of depressed patients (with or without a history of suicide) and healthy controls, the editing changes and the expression and alteration of the activity of ADARS.
Over two years, 600 participants will be recruited: * 225 subjects with current major depressive episode and an history of suicide attempt (depressed suicide attempters) * 225 subjects with current major depressive episode but with no personal history of suicide attempt (affective controls) * 150 subjects with no history of psychopathology whole life (healthy controls) Each patient will attend a total of 3visits during a follow-up period of 6 months +/- 15 days (inclusion, visit at 3 and 6 months).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
600
All the participants will performed the same evaluations and blood analysis : * A clinical assessment by psychiatrist * Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits… * A neuropsychological assessment for the evaluations of cognitive performances * A routine blood sampling to the realization of a standard blood test * A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript.
University Hospital
Montpêllier, France
Evolution of the modification of the expression of Adenosine deaminases acting on RNA (ADARs) and of the editing profile of phospho-diesterase 8A (PDE8A)
Studying ADARs expression and RNA editing of genes associated with SB, including PDE8A and comparison of these results between healthy controls and depressed patients with or without history of SB
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression of ADAR1a enzymes
Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression and RNA editing of Spindle And Kinetochore Associated protein 2 (SKA2)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression of ADAR1b enzymes
Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression of ADAR2 enzymes
Comparison of the profiles of ADARs expression and PDE8A editing between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression and RNA editing of Spermidine/Spermine N1-Acetyltransferase 1 (SAT1)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression and RNA editing of Interleukins (ILs)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression and RNA editing of Chemokines (CXCLs)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression and RNA editing of Brain derived Neurotrphic factor (BDNF)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression and RNA editing of Cluster of differentiation 24 (CD24)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression and RNA editing of Three prime repair exonuclease 1 (TREX1)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression and RNA editing of Interferon stimulated gene 15 (ISG15)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression and RNA editing of Tumor necrosis factor alpha (TNF alpha)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression and RNA editing of Vascular endothelial growth factor (VEGF)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression and RNA editing of Hydroxytryptamine receptor 2A (HTR2A)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
Modification of the expression and RNA editing of insulin-like growth factor protein 7 (IGFB7)
Comparison between non suicidal and suicidal depressed patients and healthy controls
Time frame: At the inclusion visit, 3 months and 6 months after the inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.